Profile data is unavailable for this security.
About the company
bioAffinity Technologies, Inc. is a biotechnology company focused on commercializing noninvasive tests for the detection of early-stage cancer and lung disease. The Company addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatment. Its segments include Diagnostic Research and Development (R&D) and Laboratory Services. Its Diagnostic R&D segment includes research and development and clinical development on diagnostic tests. Its Laboratory services include all the operations of Village Oaks and PPLS, in addition to sales and marketing of CyPath Lung from bioAffinity. Its first product, CyPath Lung, addresses the need for noninvasive detection of early-stage lung cancer. The CyPath Lung test enables physicians to more confidently identify patients who will likely benefit from timely intervention and more invasive follow-up procedures and those who are likely without lung cancer and should continue routine screening.
- Revenue in USD (TTM)4.94m
- Net income in USD-8.37m
- Incorporated2014
- Employees75.00
- LocationbioAffinity Technologies Inc22211 West Interstate-10, Suite 1206SAN ANTONIO 78257United StatesUSA
- Phone+1 (210) 698-5334
- Fax+1 (916) 443-1908
- Websitehttps://bioaffinitytech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Correlate Energy Corp | 7.95m | -13.85m | 24.97m | 19.00 | -- | -- | -- | 3.14 | -0.3747 | -0.3747 | 0.2157 | -0.145 | 2.76 | -- | 26.10 | 418,160.50 | -481.76 | -315.47 | -- | -- | 17.98 | 15.42 | -174.38 | -201.03 | -- | -1.07 | -- | -- | 122.20 | 46.12 | -78.54 | -- | -- | -- |
| Medicine Man Technologies Inc | -100.00bn | -100.00bn | 25.33m | 729.00 | -- | 0.339 | -- | -- | -- | -- | -- | 1.33 | -- | -- | -- | -- | -- | -8.33 | -- | -9.85 | -- | 45.57 | -- | -15.71 | 0.2457 | -- | 0.6059 | -- | 8.20 | 78.78 | -62.56 | -- | 200.89 | -- |
| Biora Therapeutics Inc | 544.00k | -111.08m | 25.55m | 58.00 | -- | -- | -- | 46.97 | -7.13 | -7.12 | 0.0267 | -3.29 | 0.0143 | -- | 0.6594 | 9,379.31 | -291.43 | -122.84 | -482,965.20 | -369.01 | -- | -- | -20,419.48 | -415.10 | -- | -- | -- | -- | -98.69 | -87.44 | -154.63 | -- | -53.68 | -- |
| Cocrystal Pharma Inc | 0.00 | -16.75m | 25.74m | 12.00 | -- | 1.14 | -- | -- | -1.65 | -1.65 | 0.00 | 2.22 | 0.00 | -- | -- | 0.00 | -52.03 | -50.94 | -56.92 | -52.77 | -- | -- | -- | -1,501.78 | -- | -- | 0.00 | -- | -- | -- | 53.69 | -- | 33.34 | -- |
| Qilian International Holding Group Ltd | 46.47m | -7.78m | 25.96m | 298.00 | -- | 0.6067 | -- | 0.5587 | -0.2176 | -0.2176 | 1.30 | 1.20 | 0.8027 | 6.45 | 33.30 | 155,944.60 | -14.03 | 2.71 | -16.84 | 3.86 | 3.77 | 11.66 | -17.48 | 2.72 | 4.43 | -0.4812 | 0.0107 | 26.11 | -28.35 | -1.60 | -822.64 | -- | 12.86 | -- |
| Aspira Women's Health Inc | 8.99m | -14.74m | 26.14m | 64.00 | -- | -- | -- | 2.91 | -1.33 | -1.33 | 0.8698 | -0.1104 | 0.9637 | 13.76 | 5.83 | 140,484.40 | -158.00 | -110.58 | -395.41 | -151.88 | 58.84 | 45.23 | -163.95 | -334.08 | 1.11 | -- | 3.10 | -- | 11.85 | 24.56 | 44.15 | -- | -26.65 | -- |
| BioVie Inc | 0.00 | -37.18m | 26.30m | 18.00 | -- | 1.39 | -- | -- | -0.9626 | -0.9626 | 0.00 | 0.3104 | 0.00 | -- | -- | 0.00 | -94.32 | -456.35 | -149.75 | -1,810.88 | -- | -- | -- | -- | -- | -- | 0.2969 | -- | -- | -- | -92.67 | -- | -- | -- |
| Akari Therapeutics PLC (ADR) | -100.00bn | -100.00bn | 26.66m | 9.00 | -- | -- | -- | -- | -- | -- | -- | -0.4449 | -- | -- | -- | -- | -- | -149.95 | -- | -435.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 43.61 | -- | -- | -- |
| bioAffinity Technologies Inc | 4.94m | -8.37m | 26.81m | 75.00 | -- | 4.91 | -- | 5.43 | -0.9197 | -0.9197 | 0.5416 | 0.4687 | 0.5334 | 318.22 | 8.70 | 65,839.60 | -90.38 | -- | -104.93 | -- | 32.88 | -- | -169.42 | -- | 2.21 | -- | 0.1782 | -- | 52,660.42 | -- | 2.66 | -- | -- | -- |
| Unity Biotechnology Inc | 0.00 | -34.78m | 26.86m | 19.00 | -- | 1.12 | -- | -- | -2.33 | -2.33 | 0.00 | 1.43 | 0.00 | -- | -- | 0.00 | -40.18 | -47.21 | -48.47 | -53.51 | -- | -- | -- | -6,395.92 | -- | -- | 0.00 | -- | -100.00 | -- | 10.36 | -- | -61.28 | -- |
| Lisata Therapeutics Inc | 0.00 | -20.05m | 27.08m | 25.00 | -- | 0.6299 | -- | -- | -2.46 | -2.46 | 0.00 | 5.18 | 0.00 | -- | -- | 0.00 | -35.01 | -45.97 | -38.40 | -50.47 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 61.57 | -- | -- | -- |
| SAB Biotherapeutics Inc | 2.60m | -39.87m | 27.17m | 57.00 | -- | 0.5143 | -- | 10.44 | -6.26 | -6.26 | 0.396 | 5.72 | 0.0456 | -- | 5.44 | 45,657.37 | -69.91 | -- | -86.60 | -- | -- | -- | -1,531.84 | -- | -- | -- | 0.0762 | -- | -90.63 | -- | -125.14 | -- | -- | -- |
| Alterola Biotech Inc | 0.00 | -2.88m | 27.17m | 1.00 | -- | -- | -- | -- | -0.0027 | -0.0027 | 0.00 | -0.001 | 0.00 | -- | -- | 0.00 | -47.24 | -- | -63.88 | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | -- | -- | 73.07 | -- | -- | -- |
| Spruce Biosciences Inc | 10.13m | -46.75m | 27.86m | 22.00 | -- | 0.4182 | -- | 2.75 | -1.15 | -1.15 | 0.2483 | 1.62 | 0.0894 | -- | -- | 349,206.90 | -41.26 | -41.24 | -50.47 | -46.49 | -- | -- | -461.67 | -1,774.39 | -- | -114.54 | 0.0423 | -- | -- | -- | -3.77 | -- | -- | -- |
| Equillium Inc | 37.89m | -12.13m | 28.24m | 44.00 | -- | 1.34 | -- | 0.7452 | -0.3476 | -0.3476 | 1.08 | 0.5983 | 0.6568 | -- | 8.95 | 861,227.30 | -21.02 | -46.81 | -39.66 | -57.36 | -- | -- | -32.01 | -328.35 | -- | -- | 0.00 | -- | 128.97 | -- | 78.64 | -- | 7.48 | -- |
Data as of Jun 11 2024. Currency figures normalised to bioAffinity Technologies Inc's reporting currency: US Dollar USD
2.08%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 70.33k | 0.61% |
| Geode Capital Management LLCas of 31 Mar 2024 | 42.08k | 0.37% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 37.50k | 0.33% |
| CapFinancial Partners LLCas of 31 Mar 2024 | 27.89k | 0.24% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 17.60k | 0.15% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 13.66k | 0.12% |
| Creative Planning LLCas of 31 Mar 2024 | 12.10k | 0.11% |
| Sheaff Brock Investment Advisors LLCas of 31 Mar 2024 | 10.00k | 0.09% |
| IFP Advisors, Inc.as of 31 Dec 2023 | 5.00k | 0.04% |
| Tower Research Capital LLCas of 31 Mar 2024 | 3.35k | 0.03% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
